NUCRYST COMPLETES PATIENT ENROLLMENT IN ATOPIC DERMATITIS STUDY

Nucryst Pharmaceuticals has announced the completion of patient enrollment in the second Phase II clinical trial with its lead pharmaceutical product candidate, a topical cream formulation of its nanocrystalline silver (NPI 32101). The investigational drug is being studied for the treatment of atopic dermatitis, a common form of eczema.

In total, 409 patients, aged 2 to 17 years of age, with mild to moderate eczema, have been enrolled to be treated for up to 12 weeks in a double-blind, randomized, placebo-controlled study involving 29 clinical sites across the U.S. and Canada.

Patients in the study are being treated with one of three cream formulations -- either 1 percent or 2 percent concentrations of NPI 32101 or with a placebo.